|Bid||208.00 x 1200|
|Ask||220.95 x 800|
|Day's Range||217.01 - 220.48|
|52 Week Range||136.44 - 220.48|
|Beta (3Y Monthly)||0.92|
|PE Ratio (TTM)||64.27|
|Earnings Date||Oct 21, 2019 - Oct 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||213.45|
Heart valve systems from Edwards Lifesciences Corp and Medtronic Plc have been approved for use in a condition that restricts blood flow from the heart in patients at low-risk of death linked to open-heart surgeries, the U.S. FDA said on Friday. The Food and Drug Administration approved two of Edwards' transcatheter heart valve systems called Sapien 3 And Sapien 3 Ultra as well as Medtronic's Evolut Transcatheter Aortic Valve Replacement (TAVR)system.
Shares of Medtronic and Edwards Lifesciences jumped Friday after the Food and Drug Administration approved their TAVR heart-valve replacement systems for healthier and younger patients.
Frost Equity Growth Fund invests in secular, consistent and cyclical growth stocks. Here's why most of the fund's bets are on secular growers.
IRVINE, Calif., Aug. 16, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards SAPIEN 3 and SAPIEN 3 Ultra transcatheter heart valve systems to the treatment of severe, symptomatic aortic stenosis (AS) patients who are determined to be at low risk of open-heart surgery. "The PARTNER 3 Trial demonstrated that low-risk patients treated with the SAPIEN 3 TAVR experienced extraordinary outcomes with 1.0 percent rates of death or disabling stroke at one year, a short length of stay and 96 percent discharged to home or self-care. SAPIEN 3 is the only valve to achieve superiority over surgery based on the prespecified primary endpoint," said Martin B. Leon, M.D., director of the Center for Interventional Vascular Therapy at NewYork-Presbyterian/Columbia University Medical Center and professor of medicine at the Columbia University College of Physicians and Surgeons.
HMS Holdings (HMSY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 24) Acasti Pharma Inc (NASDAQ: ACST ) Cardiovascular Systems ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 23) Akero Therapeutics Inc (NASDAQ: AKRO ) Mirum Pharmaceuticals ...
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 3.76% and 4.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Edwards Lifesciences reported income of $1.38 per share and $1.09 billion in sales for the quarter ended June 30. A year ago, Edwards earnings were $1.24 a share on $943.7 million in sales.
IRVINE, Calif. , July 23, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today ...
NEW YORK, NY / ACCESSWIRE / July 23, 2019 / Edwards Lifesciences Corp. (NYSE: EW ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 23, 2019 at 5:00 PM ...